CLARIVATE PLC — Form 10-Q
Filed July 29, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 62/100
What the filing says
Clarivate is pursuing a potential divestiture of all or substantially all of its Life Sciences & Healthcare business to a third party, with closing targeted by March 31, 2027. Two executive departures are documented: Henry Levy (retention agreement effective July 3, 2026) receives RSU acceleration upon closing and severance protection (18 months base salary + bonus + COBRA) if terminated within 6 months post-closing; Maroun S. Mourad (President, Intellectual Property) separated June 6, 2026, receiving $450,000 separation payment plus $30,000 COBRA reimbursement and continued salary through September 30, 2026.
Why this rating
Divestiture of a major business segment is material, but timing (by March 31, 2027) and buyer/terms remain unspecified. Two executive exits are modest in isolation. Combined, these represent meaningful but not transformational change relative to $1.3B market cap.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.